White Paper

Streamlining The Upstream Workflow For Plasmid DNA Manufacturing

By Kayla J. Spivey, Thermo Fisher Scientific

Thermo Fisher

With the demand created by mRNA vaccines and compounded by the emerging cell and gene therapy market, the need for large-scale production of GMP-grade materials for biological products has never been greater.

Finding a way to increase manufacturing capacity while maintaining high-quality standards poses a unique challenge. The demand for reproducible, high-quality, and customizable bioprocessing material is forecasting its continued growth through 2025.

Culture medium and fermentation protocols are pivotal in maintaining a high-quality optimal percent yield while minimizing contaminants that will need to be removed during purification and downstream process steps. Here we will discuss the scalable process workflow solutions available from initial R&D investment to clinical testing, and commercialization.

VIEW THE WHITE PAPER!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of BioProcess Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: